McKesson (MCK)
(Delayed Data from NYSE)
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Fresenius Medical (FMS) Sinks on Potential Rise in Competition
by Zacks Equity Research
Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.
McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Merit Medical's (MMSI) New Launch to Expand Its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Add Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
NextGen's (NXGN) AI-Based Ambient Assist to Expedite Care Plans
by Zacks Equity Research
NextGen's (NXGN) Ambient Assist will help reduce significant time by summarizing appointments and preparing care plans using AI-driven technology in real time.
Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark
by Zacks Equity Research
Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
4 Stocks to Buy From the Prospering Dental Supplies Industry
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity
by Zacks Equity Research
Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.
DexCom (DXCM) to Launch Latest CGM System G7 in Canada
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Three Reasons to Add PacBio (PACB) Stock to Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats
by Zacks Equity Research
OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Add Inari Medical (NARI) Stock to Your Portfolio
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Accuray's (ARAY) Tomo C Radiation System Gets Approval in China
by Zacks Equity Research
Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.
Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery
by Zacks Equity Research
Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans
by Zacks Equity Research
Accuray's (ARAY) latest offering is likely to improve radiation treatment.
Cardinal Health (CAH) Launches Next-Gen Enteral Feeding Pump
by Zacks Equity Research
Cardinal Health's (CAH) Kangaroo OMNI enteral feeding pump, with new portable design and effectiveness in terms of personalized care, is likely to improve the quality of life for patients.